Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cannabidiol + tetrahydrocannabinol (McMaster University)
- Development stage
- Unknown
- Lead developer
- MediPharm Labs
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is an investigational oral cannabinoid oil preparation containing a 50:2 mg ratio of cannabidiol (CBD) to tetrahydrocannabinol (THC) per milliliter, formulated in medium-chain triglyceride (MCT) oil. Developed by McMaster University in collaboration with MediPharm Labs, it is being evaluated for the treatment of various DSM-5 anxiety disorders, including Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Panic Disorder (PD), and Agoraphobia. The drug acts on the endocannabinoid system, primarily targeting cannabinoid receptors (CB1 and CB2). It is currently being studied in a Phase 3 randomized, double-blind, placebo-controlled pilot trial (NCT04569760) to assess its efficacy in reducing anxiety symptoms and its impact on inflammatory markers.
- Brand names
- CBD50:2 Plus Formula
- Other names
- 50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral PreparationCannabinoid Oil Oral Preparation
02
Targets
CNR1 (Cannabinoid receptor 1)FAAH
Beyond the preview
Go deeper on cannabidiol + tetrahydrocannabinol (McMaster University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cannabidiol + tetrahydrocannabinol (McMaster University).